Compare PXLW & XLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PXLW | XLO |
|---|---|---|
| Founded | 1997 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.1M | 39.4M |
| IPO Year | 2000 | 2021 |
| Metric | PXLW | XLO |
|---|---|---|
| Price | $5.49 | $8.47 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 1 |
| Target Price | $14.33 | ★ $28.00 |
| AVG Volume (30 Days) | 49.8K | ★ 149.7K |
| Earning Date | 05-12-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | $693,000.00 | ★ $43,766,000.00 |
| Revenue This Year | $47.19 | $88.66 |
| Revenue Next Year | $30.00 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 589.88 |
| 52 Week Low | $0.46 | $0.46 |
| 52 Week High | $15.42 | $9.25 |
| Indicator | PXLW | XLO |
|---|---|---|
| Relative Strength Index (RSI) | 46.23 | 85.75 |
| Support Level | $4.84 | $0.63 |
| Resistance Level | $6.72 | $9.25 |
| Average True Range (ATR) | 0.37 | 0.56 |
| MACD | 0.02 | -0.05 |
| Stochastic Oscillator | 53.33 | 68.90 |
Pixelworks Inc is a provider of visual processing semiconductor and software solutions that enable consistently high-quality and authentic viewing experiences in a wide variety of applications. The company defines its key target markets as Mobile (smartphone and tablet), Home and Enterprise (projectors, personal video recorders (PVR), and over-the-air (OTA) streaming devices), and Cinema (creation, remastering, and delivery of digital video content). The company operates in one segment: the design, development, marketing and sale of IC solutions for use in electronic display devices. The company generates its revenue from two broad product markets: the Mobile market and the Home and Enterprise market. The majority of the revenue is earned in Japan.
Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies and immune cell engagers.